U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C35H43N5O4
Molecular Weight 597.7483
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of REVEFENACIN

SMILES

CN(CCN1CCC(CC1)OC(=Nc2ccccc2-c3ccccc3)O)C(=O)c4ccc(cc4)CN5CCC(CC5)C(=N)O

InChI

InChIKey=FYDWDCIFZSGNBU-UHFFFAOYSA-N
InChI=1S/C35H43N5O4/c1-38(34(42)29-13-11-26(12-14-29)25-40-19-15-28(16-20-40)33(36)41)23-24-39-21-17-30(18-22-39)44-35(43)37-32-10-6-5-9-31(32)27-7-3-2-4-8-27/h2-14,28,30H,15-25H2,1H3,(H2,36,41)(H,37,43)

HIDE SMILES / InChI

Molecular Formula C35H43N5O4
Molecular Weight 597.7483
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Revefenacin (trade name Yupelri is a long-acting muscarinic antagonist developed by Mylan Ireland ltd for the treatment of chronic obstructive pulmonary disease (COPD). It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation. The competitive and reversible nature of antagonism was shown with human and animal origin receptors and isolated organ preparations. In preclinical in vitro as well as in vivo models, prevention of methacholine- and acetylcholine-induced bronchoconstrictive effects was dose-dependent and lasted longer than 24 hours.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
YUPELRI

Approved Use

YUPELRI (revefenacin) inhalation solution is an anticholinergic indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Launch Date

1536537600000
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
0.105 ng/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.114 ng/mL
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.309 ng/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.577 ng/mL
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.0742 ng/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
THRX-195518 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.178 ng/mL
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.178 ng/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.948 ng/mL
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
0.0702 ng × h/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.092 ng × h/mL
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.161 ng × h/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.443 ng × h/mL
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.117 ng × h/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
THRX-195518 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.299 ng × h/mL
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
0.259 ng × h/mL
175 μg single, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: SINGLE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1.48 ng × h/mL
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
23 h
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
23.5 h
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
22.3 h
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
29%
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
29%
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
REVEFENACIN plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
42%
175 μg 1 times / day steady-state, respiratory
dose: 175 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
42%
700 μg 1 times / day steady-state, respiratory
dose: 700 μg
route of administration: Respiratory
experiment type: STEADY-STATE
co-administered:
THRX-195518 plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Other AEs: Cough, Nasopharyngitis...
Other AEs:
Cough (4%)
Nasopharyngitis (4%)
Upper respiratory tract infection (3%)
Headache (4%)
Back pain (2%)
Hypertension (1-2)
Dizziness (1-2)
Oropharyngeal pain (1-2)
Bronchitis (1-2)
Sources:
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Disc. AE: Hypertension...
AEs leading to
discontinuation/dose reduction:
Hypertension (0.2%)
Sources:
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Disc. AE: Cough, Bronchiectasis...
AEs leading to
discontinuation/dose reduction:
Cough (0.5%)
Bronchiectasis (0.2%)
Bronchospasm paradoxical (0.2%)
Hypoxia (0.2%)
Bronchitis (0.5%)
Pneumonia (0.5%)
Gastroenteritis (0.2%)
Upper respiratory tract infection (0.2%)
Atypical pneumonia (0.2%)
Pneumonia parainfluenzae viral (0.2%)
Urinary tract infection (0.2%)
Abdominal distension (0.2%)
Dry mouth (0.2%)
Oral pain (0.2%)
Headache (0.2%)
Acute myocardial infarction (0.2%)
Colon cancer (0.2%)
Sources:
AEs

AEs

AESignificanceDosePopulation
Bronchitis 1-2
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Dizziness 1-2
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Hypertension 1-2
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Oropharyngeal pain 1-2
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Back pain 2%
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Upper respiratory tract infection 3%
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Cough 4%
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Headache 4%
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Nasopharyngitis 4%
175 ug 1 times / day steady, respiratory
Recommended
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy, 64 years (range: 41 - 88 years)
Health Status: unhealthy
Age Group: 64 years (range: 41 - 88 years)
Sources:
Hypertension 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Abdominal distension 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Acute myocardial infarction 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Atypical pneumonia 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Bronchiectasis 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Bronchospasm paradoxical 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Colon cancer 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Dry mouth 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Gastroenteritis 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Headache 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Hypoxia 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Oral pain 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Pneumonia parainfluenzae viral 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Upper respiratory tract infection 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Urinary tract infection 0.2%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Bronchitis 0.5%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Cough 0.5%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
Pneumonia 0.5%
Disc. AE
175 ug 1 times / day steady, respiratory
Dose: 175 ug, 1 times / day
Route: respiratory
Route: steady
Dose: 175 ug, 1 times / day
Sources:
unhealthy
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
no
yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
no
no
no
yes
yes
yes
yes
yes
yes
yes
yes
yes
unlikely
Comment: Available information from DDI studies conducted for digoxin (P-gp substrates) suggest that the increase in exposure (AUC and Cmax) in the presence of P-gp inhibitors is expected to be generally less than 2-fold (Refer to prescribing information for digoxin). The available clinical data (total N= 115) at 350 µg dose (2 times above 175 µg) from studies 0091 and 0117 suggest that a 2-fold exposure increase was generally safe. Considering these factors, the expected increase in the systemic of revefenacin with P-gp or BCRP inhibition is unlikely to have a clinically meaningful impact on safety of the proposed dose.
Page: 56
yes
unlikely
Comment: Available information from DDI studies conducted for digoxin (P-gp substrates) suggest that the increase in exposure (AUC and Cmax) in the presence of P-gp inhibitors is expected to be generally less than 2-fold (Refer to prescribing information for digoxin). The available clinical data (total N= 115) at 350 µg dose (2 times above 175 µg) from studies 0091 and 0117 suggest that a 2-fold exposure increase was generally safe. Considering these factors, the expected increase in the systemic of revefenacin with P-gp or BCRP inhibition is unlikely to have a clinically meaningful impact on safety of the proposed dose.
Page: 56
Tox targets
PubMed

PubMed

TitleDatePubMed
Revefenacin
2006
Patents

Patents

Sample Use Guides

The recommended dose of YUPELRI (revefenacin) inhalation solution is one 175 mkg unit-dose vial administered once daily by nebulizer using a mouthpiece.
Route of Administration: Respiratory
CHO-K1 cell membrane fractions expressing human recombinant M2 or M3 mAChRs were incubated with [3H]revefenacin (18.5 Ci/mmol), [3H]glycopyrrolate (70 Ci_mmol_1), for 1 hours at
Substance Class Chemical
Created
by admin
on Sat Jun 26 13:03:56 UTC 2021
Edited
by admin
on Sat Jun 26 13:03:56 UTC 2021
Record UNII
G2AE2VE07O
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
REVEFENACIN
INN   USAN   WHO-DD  
INN   USAN  
Official Name English
1-(2-(4-((4-CARBAMOYLPIPERIDIN-1-YL)METHYL)-N-METHYLBENZAMIDO)ETHYL)PIPERIDIN-4-YL N-((1,1'-BIPHENYL)-2-YL)CARBAMATE
Systematic Name English
GSK-1160724
Code English
TD-4208
Code English
GSK1160724
Code English
REVEFENACIN [MI]
Common Name English
YUPELRI
Brand Name English
REVEFENACIN [ORANGE BOOK]
Common Name English
CARBAMIC ACID, N-(1,1'-BIPHENYL)-2-YL-, 1-(2-((4-((4-(AMINOCARBONYL)-1-PIPERIDINYL)METHYL)BENZOYL)METHYLAMINO)ETHYL)-4-PIPERIDINYL ESTER
Systematic Name English
REVEFENACIN [USAN]
Common Name English
REVEFENACIN [WHO-DD]
Common Name English
REVEFENACIN [INN]
Common Name English
BIPHENYL-2-YLCARBAMIC ACID, 1-(2-((4-(4-CARBAMOYLPIPERIDIN-1-YLMETHYL)BENZOYL)METHYLAMINO)ETHYL)PIPERIDIN-4-YL ESTER
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C29704
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
Code System Code Type Description
FDA UNII
G2AE2VE07O
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
DRUG BANK
DB11855
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
NCI_THESAURUS
C152200
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
MERCK INDEX
M12116
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
RXCUI
2102775
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
CAS
864750-70-9
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
CAS
1211931-83-7
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
NO STRUCTURE GIVEN
INN
10112
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
LACTMED
Revefenacin
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
PUBCHEM
11753673
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
DRUG CENTRAL
5303
Created by admin on Sat Jun 26 13:03:57 UTC 2021 , Edited by admin on Sat Jun 26 13:03:57 UTC 2021
PRIMARY
Related Record Type Details
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
BINDING
Kd
TARGET -> INHIBITOR
In the airways, it exhibits pharmacological effects through inhibition of M3 receptor at the smooth muscle leading to bronchodilation.
BINDING
Kd
METABOLIC ENZYME -> SUBSTRATE
TARGET -> INHIBITOR
BINDING
Kd
TRANSPORTER -> SUBSTRATE
TARGET -> INHIBITOR
BINDING
Kd
TARGET -> INHIBITOR
BINDING
Kd
BINDER->LIGAND
BINDING
Related Record Type Details
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Tmax PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC